Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000216

Purpose

The purpose of this study is to compare the clinical efficacy of maintenance on low and high doses of buprenorphine with methadone for cocaine abusing opiate addicts.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Depression
Withdrawal symptoms
Opioid and cocaine use
Social and psychological functioning
AIDS risk behavior

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000216

Locations

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Richard Schottenfeld, M.D.

Yale University

More Information

No publications provided

Study ID Numbers:	NIDA-06266-1, R01-06266-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000216 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Disease
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Narcotics
Opioid-Related Disorders
Pharmacologic Actions
Buprenorphine

Pathologic Processes
Mental Disorders
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on November 27, 2009